@article {ROH6945, author = {HYUN JIN ROH and EUN BYEOL GO and KYUNG BIN KIM and JONG HWA LEE and SANG HUN LEE}, title = {The Diagnostic Accuracy and Postoperative Outcomes of Cervical Cancer Patients for MR-invisible or MR-visible Diagnosis of Combined T2- and Diffusion-weighted 3T MRI Using the External Phased-array Receiver}, volume = {39}, number = {12}, pages = {6945--6956}, year = {2019}, doi = {10.21873/anticanres.13916}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: This study aimed to determine the diagnostic accuracy and postoperative outcomes of early-stage cervical cancer patients [2009 FIGO stages IA2-IB1 (\<2 cm)] diagnosed with magnetic resonance (MR)-invisible disease or MR-visible disease using the external phased-array receiver. Patients and Methods: Between 2007 and 2014, 110 patients with a FIGO clinical stage IA2-IB1 (\<2 cm) cervical cancer underwent primary surgical treatment after external array coil T2W and DW MR imaging following the diagnostic biopsy procedure. Results: The median histological size of MR-invisible vs. MR-visible diagnosis was 3{\textpm}6.4 mm and 16{\textpm}5.2 mm. Eighty-five of the 110 patients had histologically residual tumor. The sensitivity, specificity, PPV, and NPV of tumor diagnosis were 63.5\%, 92.0\%, 96.4\%, and 42.6\%, respectively. Histological estimates of 54 (49.1\%) MR-invisible vs. 56 (50.9\%) MR-visible diagnoses were identified as 23 true-negative (TN) and 31 false-negative (FN) vs. 54 true-positive (TP) and 2 false-positive (FP). The recurrence-free rate was 98.1\% in the MR-invisible group and 91.1\% in the MR-visible group. The overall survival rates were 100\% and 92.9\%, respectively. Conclusion: A preoperative MR-invisible diagnosis in early-stage cervical cancer patients led to a high probability of FN and was associated with underdiagnosis.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/39/12/6945}, eprint = {https://ar.iiarjournals.org/content/39/12/6945.full.pdf}, journal = {Anticancer Research} }